Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 18/20 | 0.69 |
| ▸ | KDR | P35968 | 18/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 12/20 | 0.69 |
| ▸ | KIT | P10721 | 11/20 | 0.63 |
| ▸ | CSF1R | P07333 | 2/20 | 0.63 |
| ▸ | FLT4 | P35916 | 2/20 | 0.63 |
| ▸ | CIT | O14578 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | HLA-A | P04439 | 1/20 | 0.63 |
| ▸ | RET | P07949 | 1/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.63 |
| ▸ | FRK | P42685 | 1/20 | 0.63 |
| ▸ | CDK8 | P49336 | 1/20 | 0.63 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.63 |
| ▸ | STK3 | Q13188 | 1/20 | 0.63 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.63 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.63 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.63 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24996489 | 0.82 | FLT1 (0.66) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL905634 | 0.82 | KDR (1.00) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL905657 | 0.81 | FLT1 (0.68) | FLT1KDRPDGFRBKITCSF1R | |
| Hydrochloric Acid SCHEMBL6610350 | 0.81 | KDR (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL6612202 | 0.80 | FLT1 (0.63) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL3090589 | 0.79 | FLT1 (0.57) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL29564971 | 0.79 | FLT1 (0.57) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL20431372 | 0.79 | KDR (0.73) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL905612 | 0.78 | KDR (0.76) | FLT1KDRPDGFRBKITCSF1R | |
| SCHEMBL905608 | 0.77 | KDR (0.80) | FLT1KDRPDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10463611-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2019-11-05 | — | — | US | disclosed |
| US-9779901-B2 | High temperature material compositions for high temperature thermal cutoff devices | THERM-O-DISC, INCORPORATED (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150162153-A1 | HIGH TEMPERATURE MATERIAL COMPOSITIONS FOR HIGH TEMPERATURE THERMAL CUTOFF DEVICES | THERM-O-DISC, INCORPORATED (US) | 2015-06-11 | — | — | US | disclosed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-8961832-B2 | High temperature material compositions for high temperature thermal cutoff devices | THERM-O-DISC, INCORPORATED (US) | 2015-02-24 | — | — | US | disclosed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | FLT1 2106/4885KDR 463/4885PDGFRB 1325/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | FLT1 540/4885KDR 602/4885PDGFRB 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.